Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck stock rose moderately on Thursday after reporting adjusted income of $1.87 per share on $14.59 billion in second-quarter sales. The post Merck Eyes 50-Day Line As Profit Triples And Keytruda Passes $5 Billion Mark appeared first on Investor's Business Daily.

Merck Eyes 50-Day Line As Profit Triples And Keytruda Passes $5 Billion Mark

Chevron

Keurig Dr Pepper Inc

Procter & Gamble

QUALCOMM

The U.S. equities market remains in a dip no matter how you define it. Year-to-date, the Dow Jones Industrial Average is off by 12%.

7 Stocks to Buy on the Dip

Shares of Merck & Co. Inc. MRK, -0.07% edged up 0.1% in premarket trading Thursday, after the drug maker reported second-quarter profit and sales that rose above expectations, and raised its full-year sales outlook slightly. Net income more than tripled, to $3.94 billion, or $1.55 a share, from $1.21 billion, or 48 cents a share, in the year-ago period.

Merck stock ticks up after profit more than triples to beat expectations

The drug giant said it expects 2022 sales of between $57.5 billion and $58.5 billion.

Merck Tops Profit Estimates on Strong Keytruda and Gardasil Sales

Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer drug Keytruda.

Merck quarterly profit tops Wall Street view on strong Keytruda sales

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2022. “I continue to be immensely proud of how the Merck team is performing in all facets of our business — scientifically, commercially and operationally,” said Robert M. Davis, chief executive officer and president. “Our strategy is working and our future is bright. I am very confident that we are well-positioned to achieve our near-

Merck Announces Second-Quarter 2022 Financial Results

ON Semiconductor

Valhi

Exxon Mobil

Inflation remains on fire, CPI reached 9.1% and the Fed continues to hike rates to curb inflation. Negative sentiment has investors hyper-sensitive to declines in their portfolios. With fear moving the markets, investors should consider stocks that can weather all storms.

Top 5 Stocks To Buy For Second Half 2022

Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee.

Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator

Merck is a strong pharmaceutical company with blockbuster drugs and a promising coronavirus treatment. Its robust top-line growth should more than support its pipeline, including 8 new potential drugs by 2030.

Why Merck Offers Plenty Of Value At Current Levels

AbbVie

Activision Blizzard

Enphase Energy

Enterprise Products Partners

Energy Transfer LP Unit

Lockheed Martin

Wells Fargo

Young investors are taking their share of lumps in the S&P 500. But they're still enjoying some stock winners, too.

Very Young Investors Are Up Double-Digit Percentages On 10 Stocks

Seagen

Seattle area biotech company Seagen released early data on a trial of its drug Padcev combined with Merck's Keytruda in patients with certain types of urothelial cancer.

Seagen releases data on combination therapy with Merck drug amid acquisition reports

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company's common stock for the fourth quarter of 2022. Payment will be made on Oct. 7, 2022, to shareholders of record at the close of business on Sept. 15, 2022. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of

Merck Announces Fourth-Quarter 2022 Dividend

Comcast

Southwest Airlines

Tilray Brands

Valero Energy

The three major U.S. equity indexes closed mixed on Monday. The Dow Jones Industrial Average added 0.28%, the S&P 500 closed up 0.13%, and the Nasdaq Composite fell 0.43%.

Earnings Previews: Comcast, Merck, Southwest Airlines, Tilray, Valero Energy

Agree Realty

Cal-Maine Foods

The July FOMC meeting is this week, and many investors are on edge as the markets remain in flux following months of rate hikes that led to negative sentiment. With CPI reaching 9.1%, the likelihood of a hawkish Federal Reserve going forward is strong, and investors will continue to speculate that a recession is on the rise.

3 Top Defensive Stocks On The Eve Of The July Fed Meeting

Pfizer

Pfizer could be left with up to 70 million surplus courses of Paxlovid by the end of 2022, data firm Airfinity warned, but the drug is still on track to be one of the year's biggest.

Weak Demand For Covid Antivirals Dampens Roaring Sales

Bank of America

DTE Energy

PepsiCo

Republic Services

Walmart

Mortgage applications tumbled last week to their lowest levels in 22 years. First quarter gross domestic product came in at -1.6% and the Atlanta Fed GDPNOW tracker as of July 19 had the second-quarter GDP at the same -1.6%, and we will find out this week just how accurate that number is on Thursday.

The Recession Is Already Here – 7 Goldman Sachs Conviction List Dividend Stocks Can Survive

Merck (NYSE: MRK) is scheduled to report its Q2 2022 results on Thursday, July 28. We expect the company to have a robust Q2, with revenue falling in-line and earnings expected to be slightly above the consensus estimates.

Will Merck Stock Rise After Its Q2 Results?

Albemarle

Hershey

Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.

Three Watchlist Stocks to Capitalize on Sector Rotation

Year-to-date, Merck shares are well in the green, increasing nearly 20% in value and easily outperforming its Zacks Industry.

Merck Q2 Preview: Double-Digit Earnings Growth in Store?

Biogen

Bristol-Myers

Eli Lilly

The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal Trade Commission.

2nd-Quarter Earnings Results Could Impact Drug Company Shares

Coca-Cola

McDonald's

Microsoft

Visa

Chevron and Merck are on deck to report earnings, along with nearly a dozen other Dow Jones stocks. But outlooks are widely mixed.

Dow Jones Stocks Brace For Huge Earnings Week

Schaeffer's Investment Research was built from scratch on Bernie Schaeffer's vision of providing accessible professional-grade trading information to retail traders.

Blue-Chip Drug Stock Could Keep Lapping Broader Market

Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.

Merck's (MRK) Keytruda Head and Neck Cancer Study Fails

Pfizer and Merck could thrive during a recession. As recession fears have gripped the stock market, both have outperformed.

2 Pharma Stocks for a Recession

Merck's share price has been climbing, up ~13% since my last bullish note. The company began the year strongly, with $15.7bn revenues generated in Q122, and the FY22 forecast is for an 18% uplift to ~$57.5bn.

News for Merck Stock (MRK)